Andrew J. Leidner, Harrell W. Chesson, Fujie Xu, John W. Ward, Philip R. Spradling, Scott D. Holmberg – 11 February 2015 – New treatments for hepatitis C virus (HCV) may be highly effective but are associated with substantial costs that may compel clinicians and patients to consider delaying treatment. This study investigated the cost‐effectiveness of these treatments with a focus on patients in early stages of liver disease.

Didac Carmona‐Gutierrez, Andreas Zimmermann, Frank Madeo – 11 February 2015

James L. Boyer – 11 February 2015

Nisanne S. Ghonem, David N. Assis, James L. Boyer – 11 February 2015 – Cholestasis, including primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), results from an impairment or disruption of bile production and causes intracellular retention of toxic bile constituents, including bile salts. If left untreated, cholestasis leads to liver fibrosis and cirrhosis, which eventually results in liver failure and the need for liver transplantation.

Nisanne S. Ghonem, David N. Assis, James L. Boyer – 11 February 2015 – Cholestasis, including primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), results from an impairment or disruption of bile production and causes intracellular retention of toxic bile constituents, including bile salts. If left untreated, cholestasis leads to liver fibrosis and cirrhosis, which eventually results in liver failure and the need for liver transplantation.

Farhan Haq, Sung‐Min Ahn – 11 February 2015

Matias Avila, Carmen Berasain – 11 February 2015

Boris Blechacz, Lopa Mishra – 11 February 2015

Nadia Panera, Sara Ceccarelli, Valerio Nobili, Anna Alisi – 11 February 2015

Vincent Di Martino, Caroline Coutris, Jean‐Paul Cervoni, Stavros Dritsas, Delphine Weil, Carine Richou, Claire Vanlemmens, Thierry Thevenot – 11 February 2015 – Identifying cirrhosis with a poor short‐term prognosis remains crucial for improving the allocation of liver grafts.